NasdaqGS - Nasdaq Real Time Price USD

Ventyx Biosciences, Inc. (VTYX)

5.13 +0.76 (+17.39%)
At close: 4:00 PM EDT
5.13 0.00 (0.00%)
After hours: 4:11 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating Expense
207,210.00
207,994.00
113,136.00
67,147.00
7,050.00
--
Operating Income
-207,210.00
-207,994.00
-113,136.00
-67,147.00
-7,050.00
--
Net Non Operating Interest Income Expense
14,679.00
15,074.00
4,669.00
-21.00
-358.00
--
Other Income Expense
-72.00
-42.00
41.00
-16,578.00
-20,766.00
--
Pretax Income
-192,603.00
-192,962.00
-108,426.00
-83,746.00
-28,174.00
--
Net Income Common Stockholders
-192,603.00
-192,962.00
-108,426.00
-85,298.00
-28,174.00
--
Diluted NI Available to Com Stockholders
-192,603.00
-192,962.00
-108,426.00
-85,298.00
-28,174.00
--
Basic EPS
-3.24
--
-2.07
-6.65
-1.33
-2.18
Diluted EPS
-3.24
--
-2.07
-6.65
-1.33
-2.18
Basic Average Shares
59,590.74
--
52,471.00
12,825.60
21,120.09
1,988.59
Diluted Average Shares
59,590.74
--
52,471.00
12,825.60
21,120.09
1,988.59
Total Operating Income as Reported
-207,210.00
-207,994.00
-113,136.00
-67,147.00
-7,050.00
--
Total Expenses
207,210.00
207,994.00
113,136.00
67,147.00
7,050.00
--
Net Income from Continuing & Discontinued Operation
-192,603.00
-192,962.00
-108,426.00
-83,746.00
-28,174.00
--
Normalized Income
-192,603.00
-192,962.00
-108,426.00
-72,695.00
-7,409.00
--
Interest Income
14,679.00
15,074.00
4,669.00
78.00
--
--
Interest Expense
--
--
--
99.00
358.00
146.00
Net Interest Income
14,679.00
15,074.00
4,669.00
-21.00
-358.00
--
EBIT
-207,210.00
-207,994.00
-113,136.00
-83,647.00
-27,816.00
--
EBITDA
-205,995.00
-207,053.00
-112,666.00
-83,617.00
-27,816.00
--
Reconciled Depreciation
1,215.00
941.00
470.00
30.00
--
--
Net Income from Continuing Operation Net Minority Interest
-192,603.00
-192,962.00
-108,426.00
-83,746.00
-28,174.00
--
Total Unusual Items Excluding Goodwill
--
--
--
-11,051.00
-20,765.00
--
Total Unusual Items
--
--
--
-11,051.00
-20,765.00
--
Normalized EBITDA
-205,995.00
-207,053.00
-112,666.00
-72,566.00
-7,051.00
--
12/31/2019 - 10/21/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AMLX Amylyx Pharmaceuticals, Inc.
1.7100
-1.16%
 
SRRK Scholar Rock Holding Corporation
10.33
-3.19%
 
MGNX MacroGenics, Inc.
4.3400
-4.62%
 
SLRN Acelyrin, Inc.
4.0500
-1.94%
 
AKRO Akero Therapeutics, Inc.
19.50
+6.44%
 
RAPT RAPT Therapeutics, Inc.
4.0750
-2.51%
 
SGMT Sagimet Biosciences Inc.
5.17
+7.26%
 
TYRA Tyra Biosciences, Inc.
16.43
-5.14%
 
DSGN Design Therapeutics, Inc.
4.2100
-3.44%
 
LRMR Larimar Therapeutics, Inc.
7.38
+4.24%